Home Applications 220073 Application 220073
Type NDA
Sponsor BRISTOL Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 ELIQUIS SPRINKLE APIXABAN FOR SUSPENSION;ORAL 0.15MG Yes Yes 002 ELIQUIS APIXABAN TABLET;ORAL 5MG No No 003 ELIQUIS APIXABAN TABLET;ORAL 0.5MG No No 004 ELIQUIS APIXABAN SUSPENSION;ORAL 0.15MG No No
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N220073-001 ELIQUIS SPRINKLE APIXABAN 0.15MG FOR SUSPENSION / ORAL RLD, RS 2025-04-17
Orange Book patents# Current patent rows page 1 of 1 · 4 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N220073-001 6967208 2026-11-21 U-4180 Drug substance, Drug product 2025-05-16 N220073-001 6967208*PED 2027-05-21 Pediatric extension N220073-001 11896586 2040-11-22 U-4180 Drug product 2025-05-16 N220073-001 11896586*PED 2041-05-22 Pediatric extension
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 2 matching rows.
Application-product, Exclusivity code, Expiration table Application-product Exclusivity code Expiration N220073-001 NP 2028-04-17 N220073-001 PED 2028-10-17
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-11-14 07:37:17 2026-10 N220073-001 ELIQUIS SPRINKLE 0.15MG FOR SUSPENSION / ORAL RLD, RS 2025-04-17 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N220073-001 ELIQUIS SPRINKLE 0.15MG FOR SUSPENSION / ORAL RLD, RS 2025-04-17 c2088c7a36db…2026-09-14 22:38:34 2026-08 N220073-001 ELIQUIS SPRINKLE 0.15MG FOR SUSPENSION / ORAL RLD, RS 2025-04-17 84e616aacf4f…2026-08-18 06:07:40 2026-07 N220073-001 ELIQUIS SPRINKLE 0.15MG FOR SUSPENSION / ORAL RLD, RS 2025-04-17 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N220073-001 ELIQUIS SPRINKLE 0.15MG FOR SUSPENSION / ORAL RLD, RS 2025-04-17 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N220073-001 ELIQUIS SPRINKLE 0.15MG FOR SUSPENSION / ORAL RLD, RS 2025-04-17 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N220073-001 ELIQUIS SPRINKLE 0.15MG FOR SUSPENSION / ORAL RLD, RS 2025-04-17 6a471c1ec25d…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N220073-001 ELIQUIS SPRINKLE 0.15MG FOR SUSPENSION / ORAL RLD, RS 2025-04-17 a50c72e98297…
Observed Orange Book patent history# Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N220073-001 6967208 2026-11-21 U-4180 Drug substance, Drug product 2025-05-16 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220073-001 6967208*PED 2027-05-21 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220073-001 11896586 2040-11-22 U-4180 Drug product 2025-05-16 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220073-001 11896586*PED 2041-05-22 Pediatric extension d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N220073-001 6967208 2026-11-21 U-4180 Drug substance, Drug product 2025-05-16 c2088c7a36db…2026-10-15 13:18:30 2026-09 N220073-001 6967208*PED 2027-05-21 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N220073-001 11896586 2040-11-22 U-4180 Drug product 2025-05-16 c2088c7a36db…2026-10-15 13:18:30 2026-09 N220073-001 11896586*PED 2041-05-22 Pediatric extension c2088c7a36db…2026-09-14 22:38:34 2026-08 N220073-001 6967208 2026-11-21 U-4180 Drug substance, Drug product 2025-05-16 84e616aacf4f…2026-09-14 22:38:34 2026-08 N220073-001 6967208*PED 2027-05-21 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N220073-001 11896586 2040-11-22 U-4180 Drug product 2025-05-16 84e616aacf4f…2026-09-14 22:38:34 2026-08 N220073-001 11896586*PED 2041-05-22 Pediatric extension 84e616aacf4f…2026-08-18 06:07:40 2026-07 N220073-001 6967208 2026-11-21 U-4180 Drug substance, Drug product 2025-05-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N220073-001 6967208*PED 2027-05-21 Pediatric extension caaa826d4ba7…2026-08-18 06:07:40 2026-07 N220073-001 11896586 2040-11-22 U-4180 Drug product 2025-05-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N220073-001 11896586*PED 2041-05-22 Pediatric extension caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N220073-001 6967208 2026-11-21 U-4180 Drug substance, Drug product 2025-05-16 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N220073-001 6967208*PED 2027-05-21 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N220073-001 11896586 2040-11-22 U-4180 Drug product 2025-05-16 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N220073-001 11896586*PED 2041-05-22 Pediatric extension 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N220073-001 6967208 2026-11-21 U-4180 Drug substance, Drug product 2025-05-16 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N220073-001 6967208*PED 2027-05-21 Pediatric extension 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N220073-001 11896586 2040-11-22 U-4180 Drug product 2025-05-16 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N220073-001 11896586*PED 2041-05-22 Pediatric extension 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N220073-001 6967208 2026-11-21 U-4180 Drug substance, Drug product 2025-05-16 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N220073-001 6967208*PED 2027-05-21 Pediatric extension 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N220073-001 11896586 2040-11-22 U-4180 Drug product 2025-05-16 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N220073-001 11896586*PED 2041-05-22 Pediatric extension 6a471c1ec25d…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N220073-001 6967208 2026-11-21 U-4180 Drug substance, Drug product 2025-05-16 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N220073-001 6967208*PED 2027-05-21 Pediatric extension a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N220073-001 11896586 2040-11-22 U-4180 Drug product 2025-05-16 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N220073-001 11896586*PED 2041-05-22 Pediatric extension a50c72e98297…
Observed Orange Book exclusivity history# openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join ELIQUIS APIXABAN E.R. Squibb & Sons, L.L.C. e9481622-7cc6-418a-acb6-c5450daae9b0 2026-08-17 Boxed warning, Warnings, Adverse reactions Exact identifier application applno (NDA): 220073 application number: NDA220073
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Documents# Document, Submission type, Date table Document Submission type Date 83720 ORIG 2025-10-10 82025 ORIG 2025-04-28 81977 ORIG 2025-04-24